Weekly Paclitaxel as Third-line Chemotherapy in Patients With Metastatic Transitional Cell Carcinoma of Urothelial Tract: Results of a Phase II Study

被引：0
|
作者：
Rozzi, A. [1 ]
Nardoni, C. [1 ]
Corona, M. [1 ]
Falbo, T. [2 ]
De Marco, F. [3 ]
Grillenzoni, L. [3 ]
Lanzetta, G. [4 ]
机构：
[1] Ist Neurotraumatol, Clin Oncol Unit, I-00185 Grottaferrata, Italy
[2] Univ Roma La Sapienza, Dept Expt Med, Rome, Italy
[3] Ist Neurotraumatol Italiano INI Grottaferrata, Div Urol, Rome, Italy
[4] Ist Neurotraumatol Italiano INI Grottaferrata, Clin Oncol Unit, Rome, Italy
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)72059-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S518 / S518
页数：1
相关论文
共 50 条
  • [21] Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: A phase II trial of the Minnie Pearl Cancer Research Network
    Meluch, AA
    Greco, FA
    Burris, HA
    O'Rourke, T
    Ortega, G
    Steis, RG
    Morrissey, LH
    Johnson, V
    Hainsworth, JD
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (12) : 3018 - 3024
  • [22] A phase II study of paclitaxel and nedaplatin as front-line chemotherapy in Chinese patients with metastatic esophageal squamous cell carcinoma
    He, Yi-Fu
    Ji, Chu-Shu
    Hu, Bing
    Fan, Ping-Sheng
    Hu, Chang-Lu
    Jiang, Feng-Shou
    Chen, Jian
    Zhu, Lei
    Yao, Yi-Wei
    Wang, Wei
    WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (35) : 5910 - 5916
  • [23] Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers
    Seront, E.
    Rottey, S.
    Sautois, B.
    Kerger, J.
    D'Hondt, L. A.
    Verschaeve, V.
    Canon, J. -L.
    Dopchie, C.
    Vandenbulcke, J. M.
    Whenham, N.
    Goeminne, J. C.
    Clausse, M.
    Verhoeven, D.
    Glorieux, P.
    Branders, S.
    Dupont, P.
    Schoonjans, J.
    Feron, O.
    Machiels, J. -P.
    ANNALS OF ONCOLOGY, 2012, 23 (10) : 2663 - U39
  • [24] Third-line Therapy for metastatic Renal cell carcinoma
    Rexer, H.
    ONKOLOGE, 2011, 17 (12): : 1161 - 1162
  • [25] Third-line Therapy for metastatic Renal Cell Carcinoma
    Rexer, H.
    UROLOGE, 2011, 50 (10): : 1319 - 1321
  • [26] Third-line dovitinib in metastatic renal cell carcinoma
    Schmidinger, Manuela
    LANCET ONCOLOGY, 2014, 15 (03): : 245 - 246
  • [27] PHASE II STUDY OF AMRUBICIN FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER AS THIRD-LINE OR FOURTH-LINE CHEMOTHERAPY: UPDATED RESULTS
    Oizumi, Satoshi
    Harada, Toshiyuki
    Ito, Kenichiro
    Takamura, Kei
    Kuda, Tomoya
    Sugawara, Shunichi
    Watanabe, Kana
    Maemondo, Makoto
    Fujita, Yuka
    Kinoshita, Ichiro
    Inoue, Akira
    Hommura, Fumihiro
    Katsuura, Yutaka
    Akita, Hirotoshi
    Isobe, Hiroshi
    Nishimura, Masaharu
    RESPIROLOGY, 2013, 18 : 8 - 8
  • [28] Phase II study of paclitaxel associated with lipid core nanoparticles (LDE) as third-line treatment of patients with epithelial ovarian carcinoma
    Graziani, Silvia R.
    Vital, Carolina G.
    Morikawa, Aleksandra T.
    Van Eyll, Brigitte M.
    Fernandes Junior, Hezio J.
    Kalil Filho, Roberto
    Maranhao, Raul C.
    MEDICAL ONCOLOGY, 2017, 34 (09)
  • [29] Phase II study of paclitaxel associated with lipid core nanoparticles (LDE) as third-line treatment of patients with epithelial ovarian carcinoma
    Silvia R. Graziani
    Carolina G. Vital
    Aleksandra T. Morikawa
    Brigitte M. Van Eyll
    Hezio J. Fernandes Junior
    Roberto Kalil Filho
    Raul C. Maranhão
    Medical Oncology, 2017, 34
  • [30] Weekly pegylated liposomal doxorubicin and paclitaxel in patients with metastatic breast carcinoma: A phase II study
    Leonardi, Vita
    Palmisano, Valentina
    Pepe, Alessio
    Usset, Antonella
    Manuguerra, Giovanna
    Savio, Giuseppina
    De Bella, Manuela Tamburo
    Laudani, Agata
    Alu, Massimo
    Cusimano, Maria Pia
    Scianna, Caterina
    Giresi, Armando
    Agostara, Biagio
    ONCOLOGY LETTERS, 2010, 1 (04) : 749 - 753
12345